NewAmsterdam Pharma initiated with a Buy at TD Cowen

TD Cowen analyst Tyler Van Buren initiated coverage of NewAmsterdam Pharma with a Buy rating. Obicetrapib is a “best-in-class” oral CETPi drug that can be combined with standard of care to generate improved lipid lowering and a more holistic benefit, the analyst tells investors. The firm has conviction in the Phase 3 readouts of the BROOKLYN, BROADWAY and TANDEM trials in Q3, Q4, and Q1 of 2025, respectively, and estimates $3B-plus of global sales for Obicetrapib after a 2027 launch.